SPARC and Sun Pharma enter into a worldwide license agreement for SCD-044; Both the stocks end higher
Sun Pharma will be responsible for the development, regulatory filings, manufacturing and commercialization of the product globally.
Thu, 28 May 2020 15:41:00 +0530
